Lamivudine, Dolutegravir Sodium

• A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons with HIV-1 (INNOVATE Study) Ended
  2025-521918-26-00 Phase II 7 countries Viiv Healthcare UK Limited
• A study to evaluate the efficacy, safety, and tolerability of using an oral once-daily 2 drug regimen compared to an oral once-daily 3 drug … Ended
  2023-504993-40-00 Phase III 11 countries Viiv Healthcare UK Limited
• A randomised non-inferiority trial with nested PK to assess DTG/3TC fixed dose formulations for the maintenance of virological suppression i… Ended
  2024-520388-15-00 Phase III 1 country Fondazione Penta Ets
• A study to evaluate the efficacy, safety, participant choice and preference of an oral once-daily regimen or a long-acting injectable regim… Ended
  2023-503893-19-00 Phase III 4 countries Viiv Healthcare UK Limited
• Ph 3b, BIC/FTC/TAF to DTG/3TC FDC, 96 Week switch, efficacy, safety, and tolerability study in ART-experienced older adults living with HIV … Ended
  2022-503137-66-00 Phase III 8 countries Viiv Healthcare UK Limited
• Clinical Trial to Evaluate the Safety and Appropriateness of Switching from Dolutegravir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir A… Ended
  2024-511951-16-00 Phase IV 1 country Fundacion Seimc Gesida
• DTG/3TC vs BIC/FTC/TAF maintenance therapy in people living with HIV: an open-label randomized clinical trial Ended
  2024-515167-56-00 Phase III/IV 1 country Fundacion Seimc Gesida
• Virological and immunological assessment in HIV positive participants on 2DR versus 3DR in a prospective randomized controlled switch trial. Ended
  2024-515265-34-00 Phase IV 1 country Universitair Ziekenhuis Gent

Showing 1–8 of 8 trials